Endpoints News
Maplight’s stock plummets Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
27 July, 2026
sponsored by Cambrex logo
Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
Snapdragon Chemistry, together with NewAmsterdam Pharma, has received the American Chemical Society’s 2026 Green Chemistry Challenge Award for the Greener Synthetic Pathway in the Synthesis of Pharmaceuticals. Additionally, Cambrex continues to further its sustainability leadership, with its Milan facility receiving the EcoVadis Gold rating, placing it among the top 5% of organizations evaluated for environmental, social and ethical performance.
Learn More
spotlight
top stories
1. Sarepta turns to Michael Severino as CEO, looking to move past recent turmoil
2. MapLight’s schizophrenia drug dampens once-daily hopes despite Phase 2 win
3. Legend CEO Ying Huang resigns; Carvykti chief named interim leader
4. Updated: AstraZeneca sees blockbuster sales for Claudin 18.2 ADC but Ultomiris flops in rare disease
5.
news briefing
Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pill
6. AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings
7. Updated: Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B
8. Amgen shares new analysis with FDA in bid to keep Tavneos on the market
9. Updated: FDA adcomm backs popular wellness peptides, despite staff concerns
10. CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
more stories
 
in focus
Karen Weintraub
.

Trying to right itself after a rough year, Sarepta has named Michael Severino to replace longtime head Doug Ingram. Lei Lei Wu has an exclusive first interview with the new CEO.

.
Karen Weintraub
Deputy Editor, Endpoints News
Michael Severino, new Sarepta CEO
1
by Lei Lei Wu

Sarep­ta Ther­a­peu­tics has found its new CEO as it seeks to re­cov­er from a calami­tous past year.

Michael Sev­eri­no will re­place the com­pa­ny’s long­time leader...

Read the full story
2
by Ayisha Sharma

Map­Light Ther­a­peu­tics’ stock MPLT plum­met­ed more than 60% on Mon­day af­ter a once-dai­ly reg­i­men of its schiz­o­phre­nia drug missed the pri­ma­ry end­point in a mid-stage...

Read the full story
Endpoints webinars
Jul 30
1:00 pm ET
Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights
GUARDANT
Aug 19
1:00 pm ET
From pilots to production: AI across R&D, safety, regulatory, and clinical
IBM
Ying Huang at the Financial Times' Global Pharma and Biotech Summit in 2025 (courtesy Financial Times)
3
by Max Gelman

Leg­end Biotech, the de­vel­op­er of the block­buster can­cer ther­a­py Carvyk­ti, is in the mar­ket for a new CEO.

Ying Huang stepped down Fri­day af­ter serv­ing...